Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trialMichel Bazinet, Andrew Vaillant, Hrvoje Mijočević et al.|The Lancet. Gastroenterology & hepatology|2017Cited by 249